Delta-Fly Pharma Receivables

Delta-Fly Pharma posts a receivables of $20M as of June 2026. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Delta-Fly Pharma's receivables was $0. The latest reading is $20M (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Delta-Fly Pharma's financial statement story. At $20M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 4598.T's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Delta-Fly Pharma's other metric pages and overview cover the third.

Judging Delta-Fly Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $20M here, then scan peer and history charts to see if the gap is persistent.